Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discovery themes featuring this stock
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Viyash Scientific Ltd (VIYASH) is currently trading at 252.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Viyash Scientific Limited, formerly Sequent Scientific Limited, is engaged in the pharmaceutical business with a focus on animal health, formulations, and API. The company has shown solid financial performance in Q3 FY26, with revenues of ₹8,584 million and EBITDA growing by 64% YoY. It has achieved significant margin expansion, reflecting strong operational efficiencies and strategic cost optimization. The merger with Sequent Scientific Limited has enabled Viyash to unlock synergies across various business units, enhancing R&D, manufacturing capabilities, and market reach. This transformative merger has laid a strong foundation for sustained profitability and business growth. Viyash has successfully entered into strategic partnerships, including a noteworthy agreement with Boehringer Ingelheim for distributing companion animal products in India, underscoring its commitment to expanding its footprint in the animal health sector. The company is focusing on expanding its R&D capabilities, emphasizing the development of complex generics, which positions it to capture significant opportunities in the growing generics market for companion animals.
Over the past 52 weeks, Viyash Scientific Ltd has traded between a low of ₹166.20 and a high of ₹277.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Viyash Scientific Ltd has a market capitalization of approximately 10,893.49. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Viyash Scientific Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 68.18 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 10,893.49 Cr, Viyash Scientific Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Viyash Scientific Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Viyash Scientific Ltd is 68.18. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Viyash Scientific, through its wholly owned subsidiary Alivira Animal Health, is acquiring 100% of BioForLife Italia S.r.l., a pet care company based in Milan.
Standalone net sales were reported at ₹372.49 crore for March 2026, up from ₹42.33 crore in March 2025.
The stock reacted to higher Q4 FY26 revenue, a strong jump in EBITDA, margin expansion to 21.7%, and a swing in PAT to ₹66.38 crore versus a year-ago loss.
Viyash Scientific reported Q4 FY26 consolidated net profit of ₹52.11 crore, compared with a net loss of ₹26.24 crore in Q4 FY25.
Acquisition Expansion
Viyash Scientific's wholly owned subsidiary Alivira has signed a binding agreement to acquire 100% of Milan-based BioForLife Italia for ~₹188 crore, expected to close in Q2 FY27, to boost its European companion animal business.
Strategic acquisition
Viyash Scientific, via wholly owned subsidiary Alivira Animal Health, will acquire 100% of Milan‑based BioForLife Italia S.r.l. for ~₹188 crore in cash; transaction expected to close in Q2 FY27 to strengthen its European companion‑animal business.
Strategic acquisition
Alivira Animal Health (step‑down subsidiary of Viyash) entered a binding agreement on 8 Jun 2026 to acquire 100% of BioForLife Italia s.r.l. for EUR 16.975m (EUR 15m at closing, EUR 1.975m deferred); target CY2025 sales ≈ EUR 9m; subject to approvals.
Subsidiary acquisition
Alivira Ireland, step-down subsidiary of Viyash Scientific, signed a binding agreement to acquire 100% of BioForLife Italia s.r.l. for EUR 16.975m (EUR15.0m at closing; EUR1.975m deferred), subject to approvals; CY2025 sales ~EUR9.0m.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
250.50 | 11,313 Cr | 27.07 | 3.74 | 0.36 | 13.82 | 17.37 | 10.88 | ||
249.35 | 10,893 Cr | 68.18 | 3.74 | 0.00 | 7.07 | 13.01 | 4.44 | ||
4578.00 | 10,564 Cr | 40.96 | 27.51 | 1.63 | 62.53 | 75.60 | 47.15 | ||
542.30 | 10,540 Cr | 43.32 | 4.07 | 0.11 | 9.39 | 10.73 | 6.57 | ||
1680.00 | 10,279 Cr | 55.53 | 13.76 | 0.59 | 24.79 | 27.13 | 15.36 | ||
6190.00 | 10,271 Cr | 31.42 | 19.58 | 6.71 | 62.32 | 84.14 | 38.86 | ||
608.65 | 9,580 Cr | 37.54 | 2.89 | 0.48 | 7.70 | 10.95 | 4.71 | ||
| Median: 7 Co. | — | 608.65 | 10,540 Cr | 40.96 | 4.07 | 0.48 | 13.82 | 17.37 | 10.88 |
Bearish
1
Neutral
6
Bullish
7
Bearish
4
Neutral
6
Bullish
36
Bearish
3
Neutral
0
Bullish
29
Viyash Scientific Limited, formerly Sequent Scientific Limited, is engaged in the pharmaceutical business with a focus on animal health, formulations, and API. The company has shown solid financial performance in Q3 FY26, with revenues of ₹8,584 million and EBITDA growing by 64% YoY. It has achieved significant margin expansion, reflecting strong operational efficiencies and strategic cost optimization.
The merger with Sequent Scientific Limited has enabled Viyash to unlock synergies across various business units, enhancing R&D, manufacturing capabilities, and market reach. This transformative merger has laid a strong foundation for sustained profitability and business growth.
Viyash has successfully entered into strategic partnerships, including a noteworthy agreement with Boehringer Ingelheim for distributing companion animal products in India, underscoring its commitment to expanding its footprint in the animal health sector.
The company is focusing on expanding its R&D capabilities, emphasizing the development of complex generics, which positions it to capture significant opportunities in the growing generics market for companion animals.
Pharmaceuticals & Biotechnology
Pharmaceuticals
11,022 Cr
High Risk
69.0
34.1
0.5
3.7
277.05
166.20
Sales CAGR
Profit CAGR
ROE
ROCE
